CÃ©sar G AlbariÃ±o

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6230056/publications.pdf

Version: 2024-02-01

32 papers	1,818 citations	394421 19 h-index	414414 32 g-index
33 all docs	33 docs citations	33 times ranked	2300 citing authors

#	Article	IF	Citations
1	Isolation of Genetically Diverse Marburg Viruses from Egyptian Fruit Bats. PLoS Pathogens, 2009, 5, e1000536.	4.7	549
2	Marburg Virus Infection Detected in a Common African Bat. PLoS ONE, 2007, 2, e764.	2.5	330
3	Recovery of Recombinant Crimean Congo Hemorrhagic Fever Virus Reveals a Function for Non-structural Glycoproteins Cleavage by Furin. PLoS Pathogens, 2015, 11, e1004879.	4.7	61
4	Lassa and Ebola virus inhibitors identified using minigenome and recombinant virus reporter systems. Antiviral Research, 2016, 136, 9-18.	4.1	61
5	High Diversity and Ancient Common Ancestry of Lymphocytic Choriomeningitis Virus. Emerging Infectious Diseases, 2010, 16, 1093-1100.	4.3	59
6	Inhibitors of cellular kinases with broad-spectrum antiviral activity for hemorrhagic fever viruses. Antiviral Research, 2015, 120, 40-47.	4.1	59
7	Statins Suppress Ebola Virus Infectivity by Interfering with Glycoprotein Processing. MBio, 2018, 9, .	4.1	58
8	25-Hydroxycholesterol Inhibition of Lassa Virus Infection through Aberrant GP1 Glycosylation. MBio, 2016, 7, .	4.1	55
9	Characterisation of infectious Ebola virus from the ongoing outbreak to guide response activities in the Democratic Republic of the Congo: a phylogenetic and in vitro analysis. Lancet Infectious Diseases, The, 2019, 19, 1023-1032.	9.1	48
10	Efficient Rescue of Recombinant Lassa Virus Reveals the Influence of S Segment Noncoding Regions on Virus Replication and Virulence. Journal of Virology, 2011, 85, 4020-4024.	3.4	46
11	Development of a reverse genetics system to generate a recombinant Ebola virus Makona expressing a green fluorescent protein. Virology, 2015, 484, 259-264.	2.4	45
12	The lipid moiety of brincidofovir is required for inÂvitro antiviral activity against Ebola virus. Antiviral Research, 2016, 125, 71-78.	4.1	44
13	Development of a reverse genetics system to generate recombinant Marburg virus derived from a bat isolate. Virology, 2013, 446, 230-237.	2.4	42
14	Identification of broadly neutralizing monoclonal antibodies against Crimean-Congo hemorrhagic fever virus. Antiviral Research, 2017, 146, 112-120.	4.1	40
15	Reverse Genetics Generation of Chimeric Infectious Junin/Lassa Virus Is Dependent on Interaction of Homologous Glycoprotein Stable Signal Peptide and G2 Cytoplasmic Domains. Journal of Virology, 2011, 85, 112-122.	3.4	38
16	Novel activities by ebolavirus and marburgvirus interferon antagonists revealed using a standardized in vitro reporter system. Virology, 2017, 501, 147-165.	2.4	38
17	Antibody-Mediated Virus Neutralization Is Not a Universal Mechanism of Marburg, Ebola, or Sosuga Virus Clearance in Egyptian Rousette Bats. Journal of Infectious Diseases, 2019, 219, 1716-1721.	4.0	28
18	Use of a Scalable Replicon-Particle Vaccine to Protect Against Lethal Lassa Virus Infection in the Guinea Pig Model. Journal of Infectious Diseases, 2018, 217, 1957-1966.	4.0	26

#	Article	IF	Citations
19	Transcriptional analysis of viral mRNAs reveals common transcription patterns in cells infected by five different filoviruses. PLoS ONE, 2018, 13, e0201827.	2.5	22
20	Recombinant Marburg viruses containing mutations in the IID region of VP35 prevent inhibition of Host immune responses. Virology, 2015, 476, 85-91.	2.4	21
21	Rousette Bat Dendritic Cells Overcome Marburg Virus-Mediated Antiviral Responses by Upregulation of Interferon-Related Genes While Downregulating Proinflammatory Disease Mediators. MSphere, 2019, 4, .	2.9	20
22	Marburg Virus Persistence on Fruit as a Plausible Route of Bat to Primate Filovirus Transmission. Viruses, 2021, 13, 2394.	3.3	20
23	The S Genome Segment Is Sufficient to Maintain Pathogenicity in Intra-Clade Lassa Virus Reassortants in a Guinea Pig Model. Frontiers in Cellular and Infection Microbiology, 2018, 8, 240.	3.9	18
24	Insights into Reston virus spillovers and adaption from virus whole genome sequences. PLoS ONE, 2017, 12, e0178224.	2.5	14
25	Small Interfering RNA Inhibition of Andes Virus Replication. PLoS ONE, 2014, 9, e99764.	2.5	12
26	Preliminary Evaluation of the Effect of Investigational Ebola Virus Disease Treatments on Viral Genome Sequences. Journal of Infectious Diseases, 2016, 214, S333-S341.	4.0	11
27	Virus fitness differences observed between two naturally occurring isolates of Ebola virus Makona variant using a reverse genetics approach. Virology, 2016, 496, 237-243.	2.4	10
28	Rapid Determination of Ebolavirus Infectivity in Clinical Samples Using a Novel Reporter Cell Line. Journal of Infectious Diseases, 2017, 216, 1380-1385.	4.0	10
29	Development of a reverse genetics system for Sosuga virus allows rapid screening of antiviral compounds. PLoS Neglected Tropical Diseases, 2018, 12, e0006326.	3.0	10
30	Identification and characterization of novel mosquito-borne (Kammavanpettai virus) and tick-borne (Wad Medani) reoviruses isolated in India. Journal of General Virology, 2018, 99, 991-1000.	2.9	9
31	Genome Sequences of Crimean-Congo Hemorrhagic Fever Virus Strains Isolated in South Africa, Namibia, and Turkey. Genome Announcements, 2017, 5, .	0.8	7
32	Lassa Virus Replicon Particle Vaccine Protects Strain 13/N Guinea Pigs Against Challenge With Geographically and Genetically Diverse Viral Strains. Journal of Infectious Diseases, 2022, 226, 1545-1550.	4.0	7